Tivozanib (AV-951)
≥99%
- Product Code: 102956
Alias:
Related CAS number: 682745-41-1
CAS:
475108-18-0
| Molecular Weight: | 454.87 g./mol | Molecular Formula: | C₂₂H₁₉ClN₄O₅ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD15146788 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Tivozanib is primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It functions as a tyrosine kinase inhibitor, specifically targeting vascular endothelial growth factor receptors (VEGFRs). By blocking these receptors, Tivozanib inhibits the growth of new blood vessels that supply tumors, effectively slowing down cancer progression. Its application is particularly beneficial for patients who have not responded well to other treatments, offering an alternative therapeutic option. The drug is administered orally, making it convenient for long-term use in managing the disease. Clinical trials have demonstrated its efficacy in improving progression-free survival in patients with advanced RCC, making it a valuable addition to the arsenal of cancer therapies.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Pale Beige To Light Brown Solid |
| Purity (%) | 98.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $349.88 |
+
-
|
| 0.025 | 10-20 days | $1,164.71 |
+
-
|
| 0.100 | 10-20 days | $3,038.57 |
+
-
|
Tivozanib (AV-951)
Tivozanib is primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It functions as a tyrosine kinase inhibitor, specifically targeting vascular endothelial growth factor receptors (VEGFRs). By blocking these receptors, Tivozanib inhibits the growth of new blood vessels that supply tumors, effectively slowing down cancer progression. Its application is particularly beneficial for patients who have not responded well to other treatments, offering an alternative therapeutic option. The drug is administered orally, making it convenient for long-term use in managing the disease. Clinical trials have demonstrated its efficacy in improving progression-free survival in patients with advanced RCC, making it a valuable addition to the arsenal of cancer therapies.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :